Zalicus Presents Data Demonstrating Advantages of State-Dependent Ion
Utility of Inactivation State Screening for the Identification of Novel Pain
Therapies Presented at RSC/SCI Symposium on Ion Channels as Therapeutic
CAMBRIDGE, Mass. -- March 19, 2013
Zalicus Inc. (Nasdaq Global Market: ZLCS) today announced that preclinical
data showing the advantages of applying Zalicus’s state dependent screening
approach to identify novel calcium channel blockers for the treatment of pain
was presented on March 18 at the 4th Annual RSC/SCI Symposium on Ion Channels
as Therapeutic Targets Conference taking place from March 18-19, 2013 in
In a poster presentation entitled “Screening for State-Dependent Blockers of
Voltage Gated Calcium Channels,” Margaret S. Lee, PhD, Vice President of
Research & Translational Medicine at Zalicus, demonstrated the utility of
inactivation state screening to identify novel, potent, selective and
state-dependent calcium channel blockers with efficacy in animal models of
inflammatory and neuropathic pain.
“Rapid neuronal firing which occurs during chronic pathological pain results
in accumulation of voltage gated calcium channels in an inactivated state. By
specifically targeting this inactivated state of these channels, it may be
possible to broaden the therapeutic window, minimize adverse effects and
increase efficacy for these promising pain therapies,” said Dr. Lee.
“Comparative screening in our cell based assays for state dependent modulation
of ion channel function has resulted in the discovery of Z160 and Z944,
Zalicus’s two most advanced novel, first-in-class calcium channel blockers.
Both Z160 and Z944 have effectively demonstrated enhanced potency for their
respective targets in the inactivated state.”
About Z160 and N-type Calcium Channel Blockers
Z160 is a first-in-class, oral, state-dependent, selective N-type calcium
channel (Cav 2.2) blocker, designed to selectively target neuronal pain
signaling by modulating neurons that are undergoing high-frequency firing.
Z160 has demonstrated efficacy in multiple animal models of neuropathic and
inflammatory pain, suggesting that it has the potential to treat a broad range
of chronic pain conditions. Additionally, clinical trials in over 200 subjects
have established Z160 as a safe and well tolerated drug candidate. N-type
calcium channels have been recognized as key targets in controlling pain
because of their key role in transmitting pain through the spinal nerves to
the brain. Zalicus has advanced Z160 into two Phase 2a proof-of-concept
clinical studies in chronic neuropathic pain and plans to report top-line data
in late 2013.
About Z944 and T-type Calcium Channel Blockers
Z944 is a novel, oral, state-dependent, selective T-type calcium channel
blocker that has demonstrated preclinical efficacy in multiple inflammatory
pain models. T-type calcium channels have been recognized as key targets for
therapeutic intervention in a broad range of cell functions and have been
implicated in pain signaling. Zalicus completed Phase 1 single and multiple
ascending dose clinical studies evaluating the safety and tolerability of Z944
in late 2012 and plans to continue further clinical development during 2013.
Zalicus Inc. (Nasdaq Global Market: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain.
Zalicus has a portfolio of proprietary clinical-stage product candidates
targeting pain such as Z160 and Z944 and has entered into multiple
revenue-generating collaborations with large pharmaceutical companies relating
to other products, product candidates and drug discovery technologies. Zalicus
applies its expertise in the discovery and development of selective ion
channel modulators and its combination high throughput screening capabilities
to discover innovative therapeutics for itself and its collaborators in the
areas of pain, inflammation, oncology and infectious disease. To learn more
about Zalicus, please visit www.zalicus.com.
This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
product candidates, their potential and the plans for their clinical and
preclinical development, the Zalicus selective Ion channel modulation
technology and related preclinical product candidates and its other business
plans. These forward-looking statements about future expectations, plans,
objectives and prospects of Zalicus and its product candidates may be
identified by words like "believe," "expect," "may," "will," "should," "seek,"
“plan” or “could” and similar expressions and involve significant risks,
uncertainties and assumptions, including risks related to the development and
regulatory approval of Zalicus’ product candidates, including risks relating
to formulation and clinical development of Z160 and Z944, the unproven nature
of the Zalicus drug discovery technologies, the Company's ability to obtain
additional financing or funding for its research and development, and those
other risks that can be found in the "Risk Factors" section of Zalicus' annual
report on Form 10-K on file with the Securities and Exchange Commission and
the other reports that Zalicus periodically files with the Securities and
Exchange Commission. Actual results may differ materially from those Zalicus
contemplated by these forward-looking statements. These forward-looking
statements reflect management’s current views and Zalicus does not undertake
to update any of these forward-looking statements to reflect a change in its
views or events or circumstances that occur after the date of this release
except as required by law.
(c) 2013 Zalicus Inc. All rights reserved.
Justin Renz, CFO, 617-301-7575
Gina Nugent, 617-460-3579
Press spacebar to pause and continue. Press esc to stop.